Several clinical trials are currently underway investigating next-generation therapies for recurrent pericarditis, including Ventyx Biosciences' VTX2735 trial, Cardiol Therapeutics' Impact of CardiolRxTM over 6 Months Following IL-1 Blocker Cessation in Pericarditis Patients (MAVERIC) trial, and Kiniksa Pharmaceuticals KPL-387, as outlined in Figure 6. Here, IL1B is linked to pericarditis.